ClinicalTrials.gg
CompletedNCT01466062Updated Jun 17, 2013Results posted

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

A Phase 3 interventional study of Palivizumab in Respiratory Syncytial Virus Infection, sponsored by AbbVie (prior sponsor, Abbott). Completed at 6 sites in Japan. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2013-06-17.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
Up to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Respiratory Syncytial Virus Infections with a site in Japan — 1 open to participants now, 5 under way, 2 of them phase 3. Respiratory Syncytial Virus Infections · Japan.

Enrollment
21st of 27
28 · median 183
Started
2011
the only one that year
Phase 3
9 of 28
none open now
Registered
1st of 28
by date
Lead sponsor
1 of 28
AbbVie (prior sponsor, Abbott)

Among the 28 studies in Respiratory Syncytial Virus Infections with a site in Japan, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2011, is one of 9 in phase 3, and was the 1st registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 28 studies in Respiratory Syncytial Virus Infections with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: Up to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Respiratory Syncytial Virus Infections with a site in Japan, or all of them as a file.
02

Study summary

To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.

03

Conditions studied

  • Respiratory Syncytial Virus Infection

Keywords

  • Immunocompromised medical conditions
  • Respiratory Syncytial Virus Infection
  • Infant
  • Newborn
  • Young children
04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Availability of parent or legal guardian who is capable and willing to give written for his/her newborn, infant or young child to participate this study.
  2. Japanese newborn, infant or young child at age of 24 months or less.
  3. The subject must meet at least one of the following medical conditions (from [a] to [h]), and must be considered by the investigator to be a suitable candidate to receive prophylactic treatment of palivizumab:

    1. Subject has been diagnosed with combined immunodeficiency (severe combined immunodeficiency, X-linked hyper-immunoglobulin M (IgM) syndrome, etc.), antibody deficiency (X-linked agammaglobulinemia, common variable immunodeficiency, non-X-linked hyper-IgM syndrome, etc.) or other immunodeficiency (Wiskott-Aldrich syndrome, DiGeorge syndrome, etc.) at the time of informed consent, or
    2. Subject has been diagnosed with infection, or
    3. Subject has been diagnosed with Down syndrome without a current hemodynamically significant congenital heart disease at the time of informed consent (subject must have an experience with persistent respiratory symptom or regular outpatient treatment due to respiratory tract infection prior to current RSV season), or
    4. Subject has a history of post organ transplantation at the time of informed consent, or
    5. Subject has a history of post bone marrow transplantation at the time of informed consent, or
    6. Subject is receiving immunosuppressive chemotherapy at the start of study drug administration, or
    7. Subject is receiving systemic high dose therapy (prednisone equivalents 0.5 mg/kg or more every other day, other than inhaler or topical use) at the start of study drug administration, or
    8. Subject is receiving other immunosuppressive therapy (azathioprine, methotrexate, mizoribine, mycophenolate mofetil, cyclophosphamide, cyclosporine, tacrolimus, cytokine inhibitors, etc.) at the start of study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Subject who meets one of the palivizumab indications already approved in Japan.

    • Subject born at 28 weeks of gestation or less and who is age of 12 months or less at the start of study drug administration.
    • Subject born at 29 - 35 weeks of gestation and who is age of 6 months or less at the start of study drug administration.
    • Subject is age of 24 months or less with a history of bronchopulmonary dysplasia requiring medical management within the 6 months prior to the study drug administration.
    • Subject is age of 24 months or less with a current hemodynamically significant congenital heart disease at the start of study drug administration.
  2. Subject requires oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure or other mechanical respiratory or cardiac support at Screening and at the start of study drug administration.
  3. Subject has a current active infection including respiratory syncytial virus infection at Screening and at the start of study drug administration.
  4. Subject has a serious concurrent medical condition (hepatic dysfunction, persistent seizure disorder, etc.) except those resulting in an immune deficiency condition or renal failure.
  5. Subject has received palivizumab prior to the study drug administration.
  6. Subject has received any other agents in the past 3 months or 5 half lives prior to the investigational drug administration (whichever is longer).
  7. Subject has a history of an allergic reaction or to constituents of the study drug.
  8. Subject has a history of serious adverse reactions or serious allergic reaction to immunoglobulin products or has a history of hypersensitivity to immunoglobulin products, blood products, or other foreign proteins.
  9. Subject whose remaining days of life are expected to be less than one year at the time of .
  10. It will be impossible to collect blood as scheduled from the subject.
  11. Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Palivizumab

    15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.

    Drug: Palivizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121

    Serum trough concentrations of palivizumab were assessed at Screening, at Day 31 (30 days after the 1st dose) and Day 121 (30 days after the 4th dose).

    Time frame: Day 1 (Screening), Day 31, Day 121

Secondary outcomes

  1. Percentage of Participants Requiring Hospitalization For Respiratory Syncytial Virus (RSV) Infection

    Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.

  2. Percentage of Participants Who Required Treatment for Respiratory Syncytial Virus (RSV) Infection

    Percentage of participants who required any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.

    Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.

  3. Duration of Hospitalization Caused by Respiratory Syncytial Virus (RSV) Infection

    Number of days of hospitalization caused by RSV infection.

    Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.

  4. Duration of Required Treatment for Respiratory Syncytial Virus (RSV) Infection

    Duration (days) of requirement for any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.

    Time frame: From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.

  5. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.

    Time frame: From the first administration of palivizumab to 100 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.

  6. Mean Baseline and Mean Change From Baseline in Systolic/Diastolic Blood Pressure at Day 121

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  7. Mean Baseline and Mean Change From Baseline in Body Temperature at Day 121

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  8. Mean Baseline and Mean Change From Baseline in Respiratory Rate at Day 121

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  9. Mean Baseline and Mean Change From Baseline in Pulse Rate at Day 121

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  10. Mean Baseline and Mean Change From Baseline in Body Weight at Day 121

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  11. Hematology: Mean Baseline and Mean Change From Baseline in Hemoglobin at Day 121

    Normal range for hemoglobin varied by the monthly age of the participant.

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  12. Hematology: Mean Baseline and Mean Change From Baseline in Hematocrit at Day 121

    Normal range for hematocrit varied by the monthly age of the participant.

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  13. Hematology: Mean Baseline and Mean Change From Baseline in White Blood Cells (WBC), Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes at Day 121

    Normal ranges for WBC, neutrophils, eosinophils, basophils, lymphocytes, and monocytes varied by the monthly age of the participant.

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  14. Hematology: Mean Baseline and Mean Change From Baseline in Red Blood Cells (RBC) and Platelet Count at Day 121

    Normal ranges for RBC and platelet count varied by the monthly age of the participant.

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  15. Blood Chemistry: Mean Baseline and Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) at Day 121

    Normal ranges for ALP, AST, and ALT varied by the monthly age of the participant.

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  16. Blood Chemistry: Mean Baseline and Change From Baseline in Total Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, and C-reactive Protein (CRP) at Day 121

    Normal ranges for total bilirubin, BUN, creatinine, and CRP varied by the monthly age of the participant.

    Time frame: Baseline (Day 1), Day 121 (30 days after the 4th dose)

  17. Urinalysis: Presence of Urine Protein, Glucose, and Occult Blood at Screening and Day 121

    The values -, -/+, 1+, 2+, 3+, and 4+ represent a range from none (-) to highest (4+) presence of protein, glucose, and occult blood in the urine. Table presents the number of participants with each value. Those categories with 0 participants to report at either time point are not included in the table below.

    Time frame: Screening, Day 121 (30 days after the 4th dose)

07

Results

Posted Jun 17, 2013

Participant flow

Participant flow — Overall Study
MilestonePalivizumab
Started28
Completed26
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

PrimarySerum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121

Serum trough concentrations of palivizumab were assessed at Screening, at Day 31 (30 days after the 1st dose) and Day 121 (30 days after the 4th dose).

Time frame:
Day 1 (Screening), Day 31, Day 121
Reported as:
Mean · µg/mL
Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121
µg/mLPalivizumab
Day 1 (Screening); n=280 ± 0
Day 31; n=2859.0 ± 12.9
Day 121; n=2691.8 ± 40.6
SecondaryPercentage of Participants Requiring Hospitalization For Respiratory Syncytial Virus (RSV) Infection
Time frame:
From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Hospitalization For Respiratory Syncytial Virus (RSV) Infection
percentage of participantsPalivizumab
Percentage of Participants Requiring Hospitalization For Respiratory Syncytial Virus (RSV) Infection0 (0.0 to 12.3)
SecondaryPercentage of Participants Who Required Treatment for Respiratory Syncytial Virus (RSV) Infection

Percentage of participants who required any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.

Time frame:
From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Treatment for Respiratory Syncytial Virus (RSV) Infection
percentage of participantsPalivizumab
Intensive-care unit0 (0.0 to 12.3)
Oxygen supplementation0 (0.0 to 12.3)
Mechanical ventilation0 (0.0 to 12.3)
Extracorporeal membrane oxygenation0 (0.0 to 12.3)
Continuous positive airway pressure0 (0.0 to 12.3)
Other mechanical respiratory support0 (0.0 to 12.3)
SecondaryDuration of Hospitalization Caused by Respiratory Syncytial Virus (RSV) Infection

Number of days of hospitalization caused by RSV infection.

Time frame:
From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.

No measurements were reported for this outcome.

SecondaryDuration of Required Treatment for Respiratory Syncytial Virus (RSV) Infection

Duration (days) of requirement for any of the investigated treatments (admission in the intensive care unit \[ICU\], oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure and other mechanical respiratory support) for disease caused by RSV infection after the initial dose to 30 days after the last dose of the study drug.

Time frame:
From the first administration of palivizumab to 30 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs

An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.

Time frame:
From the first administration of palivizumab to 100 days after the last administration of palivizumab. Mean (SD) duration of treatment was 183 (37.29) days.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs
participantsPalivizumab
Any AE27
Any AE at least "possibly" drug related0
Any AE at least "probably not" drug related7
Any "severe" AE2
Any SAE7
Any AE leading to discontinuation of study drug1
Any AE leading to death0
Death0
SecondaryMean Baseline and Mean Change From Baseline in Systolic/Diastolic Blood Pressure at Day 121
Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · mm Hg
Mean Baseline and Mean Change From Baseline in Systolic/Diastolic Blood Pressure at Day 121
mm HgPalivizumab
Baseline Systolic Blood Pressure (SBP); n=2696.1 ± 9.44
Change from Baseline in SBP at Day 121; n=26-2.4 ± 10.23
Baseline Diastolic Blood Pressure (DBP); n=2555.0 ± 9.16
Change from Baseline in DBP at Day 121; n=253.0 ± 14.56
SecondaryMean Baseline and Mean Change From Baseline in Body Temperature at Day 121
Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · degrees Celcius
Mean Baseline and Mean Change From Baseline in Body Temperature at Day 121
degrees CelciusPalivizumab
Baseline Body Temperature (BT)36.77 ± 0.346
Change from Baseline in BT at Day 12-0.11 ± 0.400
SecondaryMean Baseline and Mean Change From Baseline in Respiratory Rate at Day 121
Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · respirations per minute
Mean Baseline and Mean Change From Baseline in Respiratory Rate at Day 121
respirations per minutePalivizumab
Baseline Respiratory Rate (RR)33.4 ± 8.59
Change from Baseline in RR at Day 1211.5 ± 8.21
SecondaryMean Baseline and Mean Change From Baseline in Pulse Rate at Day 121
Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · beats per minute
Mean Baseline and Mean Change From Baseline in Pulse Rate at Day 121
beats per minutePalivizumab
Baseline Pulse Rate (PR)126.6 ± 21.91
Change from Baseline PR at Day 121-6.7 ± 26.66
SecondaryMean Baseline and Mean Change From Baseline in Body Weight at Day 121
Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · kilograms
Mean Baseline and Mean Change From Baseline in Body Weight at Day 121
kilogramsPalivizumab
Baseline Body Weight (BW)8.76 ± 1.90
Change from Baseline in BW at Day 1211.23 ± 0.71
SecondaryHematology: Mean Baseline and Mean Change From Baseline in Hemoglobin at Day 121

Normal range for hemoglobin varied by the monthly age of the participant.

Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · g/dL
Hematology: Mean Baseline and Mean Change From Baseline in Hemoglobin at Day 121
g/dLPalivizumab
Baseline Hemoglobin11.57 ± 1.56
Change from Baseline in Hemoglobin at Day 1210.14 ± 1.87
SecondaryHematology: Mean Baseline and Mean Change From Baseline in Hematocrit at Day 121

Normal range for hematocrit varied by the monthly age of the participant.

Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · percentage of red blood cells
Hematology: Mean Baseline and Mean Change From Baseline in Hematocrit at Day 121
percentage of red blood cellsPalivizumab
Baseline Hematocrit34.32 ± 4.72
Change from Baseline in Hematocrit at Day 1210.96 ± 5.43
SecondaryHematology: Mean Baseline and Mean Change From Baseline in White Blood Cells (WBC), Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes at Day 121

Normal ranges for WBC, neutrophils, eosinophils, basophils, lymphocytes, and monocytes varied by the monthly age of the participant.

Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · cells *10^3/µL
Hematology: Mean Baseline and Mean Change From Baseline in White Blood Cells (WBC), Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes at Day 121
cells *10^3/µLPalivizumab
Baseline White Blood Cells (WBC); n=256.74 ± 3.93
Change from Baseline in WBC at Day 121; n=250.24 ± 2.53
Baseline (BL) Neutrophils; n=242.60 ± 2.17
Change from BL in Neutrophils at Day 121; n=24-0.05 ± 1.60
Baseline Eosinophils; n=240.25 ± 0.26
Change from BL in Eosinophils at Day 121; n=24-0.0 ± 0.31
Baseline Basophils; n=240.04 ± 0.05
Change from Baseline in Basophils at Day 121; n=240.02 ± 0.07
Baseline Lymphocytes; n=243.36 ± 2.35
Change from BL in Lymphocytes at Day 121; n=240.31 ± 1.69
Baseline Monocytes; n=240.51 ± 0.44
Change from Baseline in Monocytes at Day 121; n=24-0.02 ± 0.38
SecondaryHematology: Mean Baseline and Mean Change From Baseline in Red Blood Cells (RBC) and Platelet Count at Day 121

Normal ranges for RBC and platelet count varied by the monthly age of the participant.

Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · cells *10^4/µL
Hematology: Mean Baseline and Mean Change From Baseline in Red Blood Cells (RBC) and Platelet Count at Day 121
cells *10^4/µLPalivizumab
Baseline Red Blood Cells (RBC)410.6 ± 70.83
Change from Baseline in RBC at Day 12122.3 ± 74.74
Baseline Platelet Count31.29 ± 19.80
Change from Baseline in Platelet Count at Day 1211.72 ± 18.35
SecondaryBlood Chemistry: Mean Baseline and Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) at Day 121

Normal ranges for ALP, AST, and ALT varied by the monthly age of the participant.

Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · U/L
Blood Chemistry: Mean Baseline and Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) at Day 121
U/LPalivizumab
Baseline ALP943.0 ± 519.10
Change from Baseline in ALP at Day 121-18.0 ± 368.35
Baseline AST39.08 ± 12.95
Change from Baseline in AST at Day 1211.54 ± 8.09
Baseline ALT31.13 ± 25.70
Change from Baseline in ALT at Day 121-3.17 ± 14.07
SecondaryBlood Chemistry: Mean Baseline and Change From Baseline in Total Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, and C-reactive Protein (CRP) at Day 121

Normal ranges for total bilirubin, BUN, creatinine, and CRP varied by the monthly age of the participant.

Time frame:
Baseline (Day 1), Day 121 (30 days after the 4th dose)
Reported as:
Mean · mg/dL
Blood Chemistry: Mean Baseline and Change From Baseline in Total Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, and C-reactive Protein (CRP) at Day 121
mg/dLPalivizumab
Baseline Total Bilirubin0.30 ± 0.14
Change from Baseline in Total Bilirubin at Day 1210.04 ± 0.15
Baseline BUN11.46 ± 4.52
Change from Baseline in BUN at Day 1210.87 ± 4.64
Baseline Creatinine0.23 ± 0.04
Change from Baseline in Creatinine at Day 1210.01 ± 0.04
Baseline CRP0.29 ± 0.42
Change from Baseline in CRP at Day 1210.03 ± 0.62
SecondaryUrinalysis: Presence of Urine Protein, Glucose, and Occult Blood at Screening and Day 121

The values -, -/+, 1+, 2+, 3+, and 4+ represent a range from none (-) to highest (4+) presence of protein, glucose, and occult blood in the urine. Table presents the number of participants with each value. Those categories with 0 participants to report at either time point are not included in the table below.

Time frame:
Screening, Day 121 (30 days after the 4th dose)
Reported as:
Number · participants
Urinalysis: Presence of Urine Protein, Glucose, and Occult Blood at Screening and Day 121
participantsPalivizumab
Protein "-" at Screening; n=2421
Protein "+/-" at Screening; n=243
Protein "-" at Day 121; n=2221
Protein "+/-" at Day 121; n=221
Glucose "-" at Screening; n=2424
Glucose "-" at Day 121; n=2222
Occult Blood "-" at Screening; n=2421
Occult Blood "+/-" at Screening; n=242
Occult Blood "1+" at Screening; n=241
Occult Blood "-" at Day 121; n=2221
Occult Blood "+/-" at Day 121; n=220
Occult Blood "1+" at Day 121; n=221

Adverse events

Collected over AEs:from time of initial study drug administration (Day 1) to 100 days after final administration of the study drug. SAEs:from screening period until 100 days after final administration of study drug. Mean (SD) duration of treatment was 183 (37.29) days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palivizumab—7/28 (25%)27/28 (96.4%)
Most frequent serious events
Most frequent serious events
EventPalivizumab
GastroenteritisInfections and infestations3/28
BronchitisInfections and infestations2/28
Duodenal StenosisGastrointestinal disorders1/28
EnterocolitisGastrointestinal disorders1/28
Gastrointestinal PerforationGastrointestinal disorders1/28
Croup InfectiousInfections and infestations1/28
Infectious PeritonitisInfections and infestations1/28
PneumoniaInfections and infestations1/28
Pneumonia BacterialInfections and infestations1/28
EncephalopathyNervous system disorders1/28
Most frequent other events
Showing 10 of 75
Most frequent other events
EventPalivizumab
Upper Respiratory Tract InfectionInfections and infestations10/28
EczemaSkin and subcutaneous tissue disorders9/28
GastroenteritisInfections and infestations7/28
InfluenzaInfections and infestations6/28
HypogammaglobulinaemiaImmune system disorders5/28
NasopharyngitisInfections and infestations5/28
Dermatitis DiaperSkin and subcutaneous tissue disorders5/28
RashSkin and subcutaneous tissue disorders5/28
ThrombocytopeniaBlood and lymphatic system disorders4/28
Hepatic Function AbnormalHepatobiliary disorders4/28

Baseline characteristics

Age Continuous
Age Continuous(months)Palivizumab
Mean14.2 ± 6.20
Sex: Female, Male
Sex: Female, Male(Participants)Palivizumab
Female11
Male17
Region of Enrollment
Region of Enrollment(participants)Palivizumab
Japan28
08

Study locations

6 sites
  • Site Reference ID/Investigator# 56847
    Hyogo, Japan
  • Site Reference ID/Investigator# 56845
    Shimotsuke, Japan
  • Site Reference ID/Investigator# 56842
    Tokyo, Japan
  • Site Reference ID/Investigator# 56844
    Tokyo, Japan
  • Site Reference ID/Investigator# 56846
    Tokyo, Japan
  • Site Reference ID/Investigator# 56843
    Yokohama, Japan
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2011
First posted
Nov 6, 2011
Start
Aug 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Jun 17, 2013
Last update
Jun 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01466062
Responsible party
Sponsor
First posted
Nov 6, 2011
Start date
Aug 2011
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Jun 17, 2013
Last update
Jun 17, 2013

Study contacts

Shigeki Hashimoto, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palivizumab

Start the discussion